These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32005004)

  • 1. Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study.
    Adinolfi LE; Petta S; Fracanzani AL; Coppola C; Narciso V; Nevola R; Rinaldi L; Calvaruso V; Staiano L; Di Marco V; Marrone A; Pafundi PC; Solano A; Lombardi R; Sasso FC; Saturnino M; Rini F; Guerrera B; Troina G; Giordano M; Craxì A
    Atherosclerosis; 2020 Mar; 296():40-47. PubMed ID: 32005004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes.
    Sasso FC; Pafundi PC; Caturano A; Galiero R; Vetrano E; Nevola R; Petta S; Fracanzani AL; Coppola C; Di Marco V; Solano A; Lombardi R; Giordano M; Craxi A; Perrella A; Sardu C; Marfella R; Salvatore T; Adinolfi LE; Rinaldi L
    Nutr Metab Cardiovasc Dis; 2021 Jul; 31(8):2345-2353. PubMed ID: 34053830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
    Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
    J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study.
    Adinolfi LE; Petta S; Fracanzani AL; Nevola R; Coppola C; Narciso V; Rinaldi L; Calvaruso V; Pafundi PC; Lombardi R; Staiano L; Di Marco V; Solano A; Marrone A; Saturnino M; Rini F; Guerrera B; Troina G; Giordano M; Craxì A; Sasso FC
    Diabetes Obes Metab; 2020 Dec; 22(12):2408-2416. PubMed ID: 32761721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events.
    Butt AA; Yan P; Shuaib A; Abou-Samra AB; Shaikh OS; Freiberg MS
    Gastroenterology; 2019 Mar; 156(4):987-996.e8. PubMed ID: 30445009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients.
    Adinolfi LE; Nevola R; Guerrera B; D'Alterio G; Marrone A; Giordano M; Rinaldi L
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1379-1382. PubMed ID: 29228501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
    Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M;
    Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
    Giordanino C; Bugianesi E; Smedile A; Ciancio A; Abate ML; Olivero A; Pellicano R; Cassader M; Gambino R; Bo S; Ciccone G; Rizzetto M; Saracco G
    Am J Gastroenterol; 2008 Oct; 103(10):2481-7. PubMed ID: 18702647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
    Sagnelli E; Stroffolini T; Sagnelli C; Cacopardo B; Andriulli A; Babudieri S; Coppola N; Gaeta GB; Almasio PL
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):676-681. PubMed ID: 29465473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
    Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
    Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
    Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
    Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.